6 Result(s)
-
Article
Open AccessHigh frequency of β-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management
Fibromatosis comprises distinct clinical entities, including sporadic extra-abdominal fibromatosis, which have a high tendency for recurrence, even after adequate resection. There are no known molecular biomar...
-
Article
Open AccessPrognosis and predictive value of KIT exon 11 deletion in GISTs
KIT exon 11 mutations are observed in 60% of gastrointestinal stromal tumours (GIST). Exon 11 codes for residues Tyr568 and Tyr570, which play a major role in signal transduction and degradation of KIT. Our aim w...
-
Article
Open AccessDNA topoisomerase IIα expression and the response to primary chemotherapy in breast cancer
The α isoform of Topoisomerase IIα (Topo IIα) is a proliferation marker as well as a target for several chemotherapeutic agents such as anthracyclines. In vitro studies have demonstrated the relationship between ...
-
Article
Open AccessSummary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002)
-
Article
pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients
Tamoxifen as sole initial therapy is gaining importance in the management of post-menopausal breast cancer patients. Age oestrogen (ER) and progesterone (PR) receptor status are accurately considered to select...
-
Article
Variation of hormonal receptor, pS2, c-erbB-2 and GSTπ contents in breast carcinomas under tamoxifen: a study of 74 cases
Seventy-four post menopausal patients with primary non-metastatic invasive ductal carcinomas of the breast were first treated with tamoxifen alone (30 mg p.o. daily) for 5 months. To study changes induced by t...
